CVE-2024-0770: European Chemicals Agency IUCLID · Incorrect Default Permissions
Affects European Chemicals Agency IUCLIDSource CVE Database V5
Not known to be exploited · CVSS 4.4 Medium.
Data as of 26 Oct 2026, 17:16 UTC
- EPSS
- 0.2% chance of exploitation in 30 days – higher than 20% of CVEsExploit Prediction Scoring System: the likelihood attackers will use this flaw soon.
CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:N/I:L/A:LExploitation evidence
Disclosed: evidence found.
CVE published 21 Jan 2024
Detectable: no evidence on record.
No public nuclei template indexed
Weaponised: no evidence on record.
No public exploit code indexed in Metasploit or Exploit-DB
Exploited in the wildExploited: no evidence on record.
Not in CISA KEV and no source reports exploitation
Observed by OffSeq MirageSeen by Mirage: no evidence on record.
No attack traffic recorded by OffSeq Mirage sensors
A missing step is not evidence of safety. Sources: cve.org (opens in a new tab), the Metasploit, Exploit-DB and nuclei-templates index as of 26 Oct 2026.
What to do
Affected software
| Product | Affected | Fixed in |
|---|---|---|
| European Chemicals Agency IUCLID | Affected
| Fixed in– |
AI-suggested
To mitigate this vulnerability, European organizations should: 1) Restrict local access to systems running IUCLID to trusted and authorized personnel only, enforcing strict user account controls and monitoring. 2) Review and manually audit the file and directory permissions of the IUCLID installation, correcting any overly permissive settings to adhere to the principle of least privilege. 3) Implement application whitelisting and integrity monitoring tools to detect unauthorized changes to IUCLID executables and configuration files. 4) Employ endpoint protection solutions that can detect and prevent privilege escalation attempts or unauthorized local modifications. 5) Maintain strict physical security controls on machines running IUCLID to prevent unauthorized local access. 6) Engage with the European Chemicals Agency or IUCLID maintainers for updates or patches, and apply them promptly once available. 7) Consider isolating IUCLID installations in controlled environments or virtual machines to limit exposure. These steps go beyond generic advice by focusing on local access control, permission auditing, and integrity monitoring specific to the IUCLID environment.
Description
A vulnerability, which was classified as critical, was found in European Chemicals Agency IUCLID 7.10.3 on Windows. Affected is an unknown function of the file iuclid6.exe of the component Desktop Installer. The manipulation leads to incorrect default permissions. The attack needs to be approached locally. VDB-251670 is the identifier assigned to this vulnerability. NOTE: The vendor was contacted early about this disclosure but did not respond in any way.